ARRIVENT BIOPHARMA, INC. Class of Warrant or Right, Outstanding
ARRIVENT BIOPHARMA, INC. (AVBP) had Class of Warrant or Right, Outstanding of 1.31 million shares as of 2026-03-31, per its 10-Q filed 2026-05-11.
Financial Statements › Notes › Other Liabilities
us-gaap:ClassOfWarrantOrRightOutstanding · last filed 2026-05-11
- 2026-03-31: Class of Warrant or Right, Outstanding 1.31M shares.
- 2025-12-31: Class of Warrant or Right, Outstanding 676.13K shares.
| Period end | Class of Warrant or Right, Outstanding |
|---|---|
| 2026-03-31 | 1.31M shares 10-Q · filed 2026-05-11 |
| 2025-12-31 | 676.13K shares 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |